InsidersTradesSigma
NovaBridge Biosciences: directors' dealings · United States · SEC (Form 4)
Explore the full directors' dealings record of NovaBridge Biosciences, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €225.5m. The latest transaction was reported on 22 June 2026 (Levée d'options). Among the most active insiders: Dennis Phillip Andrew. Every trade is openly available.
2
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
1 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 June 2026
Declarations2 total
23,695 sharesOrdinary SharesSEC:0002089237-26-000006:0
8,494 sharesOrdinary SharesSEC:0002089237-26-000006:1
2 of 2 declarations
About NovaBridge Biosciences
NovaBridge Biosciences is a company listed on the XNAS market, specializing in the development of innovative biopharmaceutical solutions. It focuses on research and commercialization of treatments for complex diseases.